

Ryuji Yamaguchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3212545/publications.pdf>

Version: 2024-02-01

20
papers

892
citations

623734

14
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

1484
citing authors

#	ARTICLE	IF	CITATIONS
1	Opa1-Mediated Cristae Opening Is Bax/Bak and BH3 Dependent, Required for Apoptosis, and Independent of Bak Oligomerization. <i>Molecular Cell</i> , 2008, 31, 557-569.	9.7	248
2	Mitochondria frozen with trehalose retain a number of biological functions and preserve outer membrane integrity. <i>Cell Death and Differentiation</i> , 2007, 14, 616-624.	11.2	94
3	Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. , 2019, 195, 13-20.		69
4	Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy. <i>PLoS ONE</i> , 2011, 6, e24102.	2.5	65
5	Dynamics of mitochondrial structure during apoptosis and the enigma of Opa1. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2009, 1787, 963-972.	1.0	52
6	Mitosis specific serine phosphorylation and downregulation of one of the focal adhesion protein, paxillin. <i>Oncogene</i> , 1997, 15, 1753-1761.	5.9	50
7	The Human Homolog of <i>Saccharomyces cerevisiae</i> CDC45. <i>Journal of Biological Chemistry</i> , 1998, 273, 18205-18209.	3.4	50
8	Unphosphorylated and tyrosine-phosphorylated forms of a focal adhesion protein, paxillin, are substrates for calpain II in vitro: Implications for the possible involvement of calpain II in mitosis-specific degradation of paxillin. <i>FEBS Letters</i> , 1994, 356, 114-116.	2.8	48
9	A Role for Ran-GTP and Crm1 in Blocking Re-Replication. <i>Cell</i> , 2003, 113, 115-125.	28.9	45
10	Paxillin association in vitro with integrin cytoplasmic domain peptides. <i>FEBS Letters</i> , 1996, 399, 53-58.	2.8	34
11	Finding a Panacea among Combination Cancer Therapies. <i>Cancer Research</i> , 2012, 72, 18-23.	0.9	28
12	Targeting cholesterol with β -cyclodextrin sensitizes cancer cells for apoptosis. <i>FEBS Letters</i> , 2015, 589, 4097-4105.	2.8	28
13	Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration. <i>Cancer Biology and Therapy</i> , 2018, 19, 745-754.	3.4	22
14	Proteasome Inhibitors Alter the Orderly Progression of DNA Synthesis during S-Phase in HeLa Cells and Lead to Rereplication of DNA. <i>Experimental Cell Research</i> , 2000, 261, 271-283.	2.6	20
15	Challenges in targeting cancer metabolism for cancer therapy. <i>EMBO Reports</i> , 2012, 13, 1034-1035.	4.5	14
16	Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis. <i>Cell Death and Disease</i> , 2011, 2, e227-e227.	6.3	11
17	VHL-deficient renal cancer cells gain resistance to mitochondria-activating apoptosis inducers by activating AKT through the IGF1R-PI3K pathway. <i>Tumor Biology</i> , 2016, 37, 13295-13306.	1.8	10
18	Deconstructing Signaling Pathways in Cancer for Optimizing Cancer Combination Therapies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1258.	4.1	2

#	ARTICLE	IF	CITATIONS
19	An Emerging Model for Cancer Development from a Tumor Microenvironment Perspective in Mice and Humans. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1225, 19-29.	1.6	2
20	Comparison of in Vitro Apoptotic Response of Chronic Lymphocytic Leukemia (CLL) Cells to Bcl-2 Antagonist ABT-737 and IAP Antagonist BV6.. <i>Blood</i> , 2009, 114, 4386-4386.	1.4	0